ASO Author Reflections: No Further Axillary Treatment is Safe if the Sentinel Nodes are Negative After Neoadjuvant Chemotherapy in cT2 cN1 Breast Cancer
- 15 November 2025
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2326-2327
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional StudyAnnals of Surgical Oncology, 2025
- Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2024
- St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer – A Brief Summary of the Consensus DiscussionBreast Care, 2023
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort studyThe Lancet Oncology, 2013
- Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2005